Insight Molecular Diagnostics Inc. — Director's Dealing 2023

Jun 13, 2023

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Oncocyte Corp (OCX)
CIK: 0001642380
Period of Report: 2023-06-09

Reporting Person: Riggs Josh (Director, CEO and President)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2023-06-09	Option to Purchase Common Stock	$0.2132	A	350000	Acquired	2033-06-09	Common Stock (350000)	Direct
2023-06-09	Option to Purchase Common Stock	$0.2132	A	800000	Acquired	2033-06-09	Common Stock (800000)	Direct

Footnotes

F1: 25% of the options will vest and thereby be exercisable after one year of continuous service from the effective date of grant, and the balance will vest and thereby be exercisable in 36 equal monthly installments commencing one year after the date of grant, subject to continuous service through the applicable vesting date.

F2: The options will vest and thereby be exercisable on December 31, 2025, based on achievement of certain specified targets with respect to the 30-day volume-weighted average price of Company's common stock, measured as of the end of each full calendar month up through December 31, 2025, subject to continuous services through December 31, 2025.